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infectious diseases among people who inject
drugs’
Joan Colom i Farran
In late 2011, the European Centre for Disease Prevention
and Control (ECDC) and European Monitoring Centre
for Drugs and Drug Addiction (EMCDDA) published
ECDC and EMCDDA Guidance: Prevention and Control
of Infectious Diseases among People Who Inject Drugs [1].
This document synthesised evidence-based good practices
and expert opinion into a body of pragmatic recommen-
dations for European policy-makers and programme
planners.
ECDC and EMCDDA Guidance is a valuable resource
for those who are addressing one of the most serious
health problems related to illegal drug use: infectious
diseases. The document focuses primarily on HIV, tuber-
culosis, hepatitis B and hepatitis C. It has the potential to
encourage political decision-making based on scientific
evidence rather than on ideological principles, and it may
also lay the groundwork for more harmonised interven-
tions within the European Union [2]. The purpose of this
commentary is to highlight key elements of the ECDC and
EMCDDA Guidance and to consider how guidance of this
nature might be further strengthened in the future.
In my opinion, the two major contributions of the docu-
ment are to identify the core values and principles that
should guide interventions and to stress the importance of
combining key interventions.
The core values and principles encompass issues such as
client confidentiality, service accessibility, non-judgmental
service provision, human rights and health promotion. It
is important to recognise the centrality of these issues
because people who use drugs are widely made the object
of stigmatization and discrimination [3]. This is a relevant
specific feature which distinguishes them from other types
of patients. This fact can condition and limit the quality
and coverage of care provided to drug users. If policies
and drug services fully incorporate the core values and
principles identified in the ECDC and EMCDDA
Guidance, without any doubt this would greatly facilitate
the implementation of the key interventions to prevent
infectious diseases.
Regarding the importance of combining key interven-
tions, efforts to prevent hepatitis C have made us keenly
aware that the prevention measures suggested in the
document will be most effective when they are integrated
with each other and provided at good coverage levels [4].
Isolated interventions or integrated interventions that are
not widely implemented will scarcely have any impact on
public health, even though they may be used to justify
questionable political decisions.
Additionally, the interventions described in ECDC and
EMCDDA Guidance include three points that I wish to
highlight.
First, the provision of sterile syringes and other drug
consumption equipment should not be made conditional
upon the exchange of used syringes. ECDC and EMCDDA
Guidance states, “In order to achieve the goal of infectious
disease prevention, easy access to needles and syringes
should be promoted and the return of needles and syr-
inges should be encouraged, but not absolutely required,
in order to receive new supplies.” This guidance embodies
the recognition that there is a need to go from exchange
to distribution with the aim of achieving higher levels of
coverage [5]. Parallel efforts should be made to recover the
maximum number of syringes distributed, but this aim
should never result in clients being restricted from acquir-
ing the sterile syringes and other supplies that they need.
Second, too many opiate substitution services in Europe
currently do not include syringe provision, or else people
are required to quit using drugs in order to be allowed to
Correspondence: Joan.colom@gencat.cat
Programme on Substance Abuse, Public Health Agency of Catalonia,
Autonomous Government of Catalonia, Barcelona, Spain
Farran BMC Infectious Diseases 2014, 14(Suppl 6):S11
http://www.biomedcentral.com/1471-2334/14/S6/S11
© 2014 Farran; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
access opiate substitution treatment. ECDC and
EMCDDA Guidance observes that according to a meta-
analysis of six United Kingdom-based studies [6], “the
two interventions acted synergistically, reducing the odds
of new [hepatitis C] infection by nearly 80% when a high
coverage of needle and syringe programmes was provided
for those who continued to inject while on opioid substi-
tution treatment.” Simultaneously receiving substitution
treatment and accessing clean equipment should be con-
sidered a key preventive strategy. Drug workers might
seek to change the situation of people who still inject
while receiving substitution therapy, but denying access
to effective interventions is not the way to accomplish
this goal.
Third, heroin-assisted therapy is briefly mentioned in
the ECDC and EMCDDA Guidance as an effective opi-
ate addiction treatment. In fact there are many studies
proving its efficacy, especially for those failing with
other substitution therapies [7]. I want to stress this
from the ECDC and EMCDDA Guidance because there
are still very few countries implementing it.
Regarding other points, I wish to present a somewhat
different perspective. ECDC and EMCDDA Guidance
highlights the strategy of integrating a range of services for
people who inject drugs into a “one-stop shop” service
delivery model. This approach has merit as a means of
reaching as many drug users as possible and providing as
many prevention activities as possible because patients
referred to standard health services often get lost,
especially when they are confronted with complex care
pathways that are difficult navigate. However, I believe
that if a drug user has the capacity to engage with health
services that are utilised by other community members, he
or she should be referred to those services. In that way, we
normalize the situation and prevent social exclusion.
Therefore, the “one-stop shop” approach should be
reserved for clients who seem unlikely to otherwise access
the services they need [8].
ECDC and EMCDDA Guidance mentions supervised
injecting facilities as a service for reducing risk beha-
viour and overdoses. I consider these facilities to be a
valuable resource for preventing the transmission of
infectious diseases among socially excluded drug users,
and in my opinion they should be emphasised much
more in any updated future version of the guidelines. I
am aware that research on those facilities is limited, but
do you really need much research to prove that injecting
inside these facilities is much safer than injecting else-
where? (It is like needing to prove that jumping from a
plane with a parachute is safer than jumping without
one, is it not?)
Also for future editions of the guidelines, I recom-
mend including strategies for preventing the transition
from non-injecting routes of drug administration to
injecting. Again, there is not much evidence on effective
programmes, but this is because little research has been
conducted on the topic. We do know, however, that
injecting strongly increases the risks associated with
drug consumption.
There is no doubt that ECDC and EMCDDA Guidance
is a valuable tool for policy-makers aiming to curb infec-
tious diseases among injecting drug users. In too many
European countries, however, moral and ideological
reasons are still being invoked to block the measures iden-
tified in the guidance, even though many of these mea-
sures are supported by strong scientific evidence of their
effectiveness. That phenomenon surely does not occur in
relation to any health condition other than drug addiction.
Ultimately the success of the ECDC and EMCDDA
Guidance and the impact on public health will depend on
how far we the policy-makers are able to move away from
moral and politically “correct” approaches.
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